Which class specifically targets aldosterone-mediated effects in heart failure?

Which class specifically targets aldosterone-mediated effects in heart failure?

• A. Mineralocorticoid receptor antagonists
• B. ACE inhibitors
• C. Beta blockers
• D. SGLT2 inhibitors

Answer: (A)

Aldosterone-driven effects in heart failure are targeted by blocking the mineralocorticoid receptor. Aldosterone promotes sodium and water retention and, in the heart and vessels, drives fibrosis and adverse remodeling. When mineralocorticoid receptors are blocked, aldosterone cannot exert these effects, leading to reduced fluid retention and mitigation of fibrotic remodeling. This mechanism is why mineralocorticoid receptor antagonists like spironolactone and eplerenone are used in heart failure with reduced ejection fraction—they improve symptoms and outcomes by directly dampening aldosterone’s harmful actions. It's important to monitor potassium and kidney function because blocking these receptors can raise potassium levels. Other drug classes, such as ACE inhibitors, beta blockers, and SGLT2 inhibitors, provide benefits in heart failure through different pathways and do not specifically antagonize aldosterone receptors.

Aldosterone-driven effects in heart failure are targeted by blocking the mineralocorticoid receptor. Aldosterone promotes sodium and water retention and, in the heart and vessels, drives fibrosis and adverse remodeling. When mineralocorticoid receptors are blocked, aldosterone cannot exert these effects, leading to reduced fluid retention and mitigation of fibrotic remodeling. This mechanism is why mineralocorticoid receptor antagonists like spironolactone and eplerenone are used in heart failure with reduced ejection fraction—they improve symptoms and outcomes by directly dampening aldosterone’s harmful actions. It's important to monitor potassium and kidney function because blocking these receptors can raise potassium levels. Other drug classes, such as ACE inhibitors, beta blockers, and SGLT2 inhibitors, provide benefits in heart failure through different pathways and do not specifically antagonize aldosterone receptors.